Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265306 | 0.87 | BACE1 (0.44) | KMT2AMEN1L3MBTL1MAPTTDP1 | |
| SCHEMBL8265568 | 0.85 | BACE1 (0.44) | KMT2AMEN1L3MBTL1MAPTBACE1 | |
| SCHEMBL8265529 | 0.85 | MEN1 (0.54) | KMT2AMEN1L3MBTL1MAPTMAPK1 | |
| SCHEMBL8264446 | 0.85 | BACE1 (0.63) | BACE1ALDH1A1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL14007503 | 0.84 | BACE1 (0.64) | KMT2AMEN1MAPTBACE1ALDH1A1 | |
| SCHEMBL14007515 | 0.82 | MEN1 (0.53) | KMT2AMEN1BACE1ALDH1A1RAB9A | |
| SCHEMBL8265215 | 0.80 | BACE1 (0.45) | KMT2AMEN1BACE1ALDH1A1APAF1 | |
| Ammonia Solution, Strong SCHEMBL5246491 | 0.79 | SMN1; SMN2 (0.45) | KMT2AMEN1L3MBTL1MAPTMAPK1 | |
| SCHEMBL8264988 | 0.77 | MEN1 (0.40) | KMT2AMEN1L3MBTL1MAPTMAPK1 | |
| SCHEMBL20270067 | 0.72 | ALDH1A1 (0.59) | KMT2AMEN1L3MBTL1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | KMT2A 1883/4885MEN1 3533/4885L3MBTL1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.